Dr. Soliman Abdul Kader Valuation Multiples

Discover revenue and EBITDA valuation multiples for Dr. Soliman Abdul Kader and similar public comparables like Astrana Health, Agilon Health, Pediatrix, Surgery Partners and more.

Dr. Soliman Abdul Kader Overview

About Dr. Soliman Abdul Kader

Dr Soliman Abdul Kader Fakeeh Hospital Co is a company whose principal activities include managing, establishing, and operating hospitals, clinics, medical, educational, and training centers. In addition to the above, the company is also managing and operating medical services, analysis and radiology laboratory, and managing and establishing pharmacies, wholesale and retail of medical equipment, maintenance of IT equipment, and software-related services. The group has three reportable segments, including medical services, which generates maximum revenue, education, trading, retail, and others. Geographically, it principally operates in the Kingdom of Saudi Arabia.


Founded

1978

HQ

Saudi Arabia

Employees

2.7K

Financials (LTM)

Revenue: $882M
EBITDA: $139M

EV

$2.4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Dr. Soliman Abdul Kader Financials

Dr. Soliman Abdul Kader reported last 12-month revenue of $882M and EBITDA of $139M.

In the same LTM period, Dr. Soliman Abdul Kader generated $223M in gross profit, $139M in EBITDA, and $74M in net income.

Revenue (LTM)


Dr. Soliman Abdul Kader P&L

In the most recent fiscal year, Dr. Soliman Abdul Kader reported revenue of $855M and EBITDA of $142M.

Dr. Soliman Abdul Kader is profitable as of last fiscal year, with gross margin of 23%, EBITDA margin of 17%, and net margin of 9%.

See analyst estimates for Dr. Soliman Abdul Kader
LTMLast FY202320242025202620272028
Revenue$882M$855M$644M$772M$855M
Gross Profit$223M$195M$171M$193M$195M
Gross Margin25%23%27%25%23%
EBITDA$139M$142M$146M$151M$142M
EBITDA Margin16%17%23%20%17%
EBIT Margin10%10%14%13%10%
Net Profit$74M$80M$77M$80M$80M
Net Margin8%9%12%10%9%
Net Debt-$53M---

Financial data powered by Morningstar, Inc.

Dr. Soliman Abdul Kader Stock Performance

Dr. Soliman Abdul Kader has current market cap of $2.2B, and enterprise value of $2.4B.

Market Cap Evolution


Dr. Soliman Abdul Kader's stock price is $9.62.

Dr. Soliman Abdul Kader share price decreased by 1.7% in the last 30 days, and by 6.8% in the last year.

Dr. Soliman Abdul Kader has an EPS (earnings per share) of $0.35.

See more trading valuation data for Dr. Soliman Abdul Kader
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2.4B$2.2B0.4%-1.7%-0.9%-6.8%$0.35

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Dr. Soliman Abdul Kader Valuation Multiples

Dr. Soliman Abdul Kader trades at 2.8x EV/Revenue multiple, and 17.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Dr. Soliman Abdul Kader

EV / Revenue (LTM)


Dr. Soliman Abdul Kader Financial Valuation Multiples

As of July 18, 2026, Dr. Soliman Abdul Kader has market cap of $2.2B and EV of $2.4B.

Dr. Soliman Abdul Kader has a P/E ratio of 29.8x.

LTMLast FY202320242025202620272028
EV/Revenue2.8x2.9x3.8x3.2x2.9x
EV/EBITDA17.6x17.3x16.8x16.2x17.3x
EV/EBIT28.6x28.7x26.5x24.6x28.7x
EV/Gross Profit11.0x12.6x14.4x12.7x12.6x
P/E29.8x27.6x28.6x27.8x27.6x
EV/FCF-(117.6x)(60.1x)(100.1x)(117.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Dr. Soliman Abdul Kader Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Dr. Soliman Abdul Kader Margins & Growth Rates

Dr. Soliman Abdul Kader grew revenue by 9% and EBITDA by 2% in the last fiscal year.

In the most recent fiscal year, Dr. Soliman Abdul Kader reported gross margin of 23%, EBITDA margin of 17%, and net margin of 9%.

See estimated margins and future growth rates for Dr. Soliman Abdul Kader

Dr. Soliman Abdul Kader Margins

Last FY202420252026202720282029
Gross Margin23%25%23%27%
EBITDA Margin17%20%17%15%
EBIT Margin10%13%10%10%
Net Margin9%10%9%8%
FCF Margin(2%)(3%)(2%)(4%)

Dr. Soliman Abdul Kader Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%20%11%9%
Gross Profit Growth30%13%1%30%
EBITDA Growth2%4%(6%)2%
EBIT Growth4%8%(14%)4%
Net Profit Growth(4%)3%1%(4%)
FCF Growth96%(40%)(15%)96%

Data powered by FactSet, Inc. and Morningstar, Inc.

Dr. Soliman Abdul Kader Operational KPIs

Dr. Soliman Abdul Kader's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.

Dr. Soliman Abdul Kader's Rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Dr. Soliman Abdul Kader's Rule of X is 38% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Dr. Soliman Abdul Kader
LTMLast FY202320242025202620272028
Rule of 4032%24%---
Bessemer Rule of X57%38%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue3%3%2%2%3%
G&A Expenses to Revenue10%10%10%10%10%
Opex to Revenue-13%12%12%13%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Dr. Soliman Abdul Kader Competitors

Dr. Soliman Abdul Kader competitors include Astrana Health, Agilon Health, Pediatrix, Surgery Partners, Topchoice Medical, Select Medical, Huaxia Eye Hospital Group, Guardian Pharmacy Service, Meinian Onehealth and Draegerwerk.

Most Dr. Soliman Abdul Kader public comparables operate across Hospitals & Clinics.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Astrana Health0.9x0.8x13.7x11.8x
Agilon Health0.3x0.3x(6.6x)(16.1x)
Pediatrix1.3x1.3x8.9x8.6x
Surgery Partners1.8x1.8x10.5x11.2x
Topchoice Medical5.5x5.2x17.2x16.6x
Select Medical-0.9x-10.2x
Huaxia Eye Hospital Group2.6x2.5x11.4x12.0x
Guardian Pharmacy Service1.8x1.8x22.0x21.0x

This data is available for Pro users. Sign up to see all Dr. Soliman Abdul Kader competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Dr. Soliman Abdul Kader

When was Dr. Soliman Abdul Kader founded?Dr. Soliman Abdul Kader was founded in 1978.
Where is Dr. Soliman Abdul Kader headquartered?Dr. Soliman Abdul Kader is headquartered in Saudi Arabia.
How many employees does Dr. Soliman Abdul Kader have?As of today, Dr. Soliman Abdul Kader has over 2K employees.
Is Dr. Soliman Abdul Kader publicly listed?Yes, Dr. Soliman Abdul Kader is a public company listed on Tadawul.
What is the stock symbol of Dr. Soliman Abdul Kader?Dr. Soliman Abdul Kader trades under 4017 ticker.
When did Dr. Soliman Abdul Kader go public?Dr. Soliman Abdul Kader went public in 2024.
Who are competitors of Dr. Soliman Abdul Kader?Dr. Soliman Abdul Kader main competitors include Astrana Health, Agilon Health, Pediatrix, Surgery Partners, Topchoice Medical, Select Medical, Huaxia Eye Hospital Group, Guardian Pharmacy Service, Meinian Onehealth, Draegerwerk.
What is the current market cap of Dr. Soliman Abdul Kader?Dr. Soliman Abdul Kader's current market cap is $2.2B.
What is the current revenue of Dr. Soliman Abdul Kader?Dr. Soliman Abdul Kader's last 12 months revenue is $882M.
What is the current revenue growth of Dr. Soliman Abdul Kader?Dr. Soliman Abdul Kader revenue growth (NTM/LTM) is 16%.
What is the current EV/Revenue multiple of Dr. Soliman Abdul Kader?Current revenue multiple of Dr. Soliman Abdul Kader is 2.8x.
What is the current EBITDA of Dr. Soliman Abdul Kader?Dr. Soliman Abdul Kader's last 12 months EBITDA is $139M.
What is Dr. Soliman Abdul Kader's EBITDA margin?Dr. Soliman Abdul Kader's last 12 months EBITDA margin is 16%.
What is the current EV/EBITDA multiple of Dr. Soliman Abdul Kader?Current EBITDA multiple of Dr. Soliman Abdul Kader is 17.6x.
How many companies Dr. Soliman Abdul Kader has acquired to date?Dr. Soliman Abdul Kader hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Dr. Soliman Abdul Kader has invested to date?Dr. Soliman Abdul Kader hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Dr. Soliman Abdul Kader

Lists including Dr. Soliman Abdul Kader

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial